



Iperion Limited

Annual Meeting
27 September 2024

Agenda

- Welcome and Introductions
- Formalities
- Presentation to Shareholders
- Q&A Discussion
- Resolutions

Formalities

- Attendance of the virtual meeting has been left open for all interested to be able to attend.
- The meeting is recorded.
- To ensure that voting is accounted for correctly, all votes will be required to be submitted electronically. For shareholders who have not voted yet via Link, but still wish to do so after the meeting, please forward your completed voting form to john.cilliers@outlook.co.nz by no later than 4pm today.
(contact John if you need a form)

Review of the year ended 31 March 2024

- Increase in interest income as result of higher bank interest rates
- Outsource Plant expense is a fixed fee of \$400k p.a. 2024 includes establishment cost.
- Admin expenses higher in 2024 mainly in audit fees, expenditure on oversight of the manufacturing plant and product marketing activities.
- Impairment expense is on trademark intangibles. Expected to be reversed once the value of sales support the intangibles valuation.
- There were no changes in the number of shares on issue

	2024 \$	2023 \$
Interest income	41,396	26,121
Outsource Manufacturing Plant	500,000	0
Administrative expenses	354,372	306,197
Impairment expense	9,283	0
Net loss	822,259	280,107
Net assets	804,081	1,626,340
Cash and Term deposits	866,481	1,593,924

Progress and current activities

- ✓ Company name changed to Iperion Limited.
- ✓ Kicked off marketing at Arabplast exhibition in Dubai (Dec'23). Since followed by other presentations in Bangkok, Singapore, Malaysia
- ✓ Pathoglaze® registered as a trademark in NZ/Australia/EU/China/Singapore. (Underway in others in accordance with the Madrid protocol)
- ✓ Certified as green technology product from GPM Global USA and further awarded as the Green Project Malaysia GPM Sustainability Award 2023 Certifications on Manufacturing Facility.
- ✓ Numerous product trials underway with customers, ranging from Germany, Japan, Taiwan etc on a range of possible application of the product (more info in following slide)
- ✓ Currently conserving cash until sales commence by some of the costs of the outsourced manufacturing plant being supported with research grants.



Pathoglaze is a durable, high potency, anti-microbial product capable of being incorporated into raw materials for other products at the point of manufacture.

For example it can be incorporated in plastics masterbatch powders prior to product moulding or it can be applied to existing products as a thin film coating.

PATHOGLAZE

Fine Powder (Additives)


- ✓ **PATHOGLAZE® Hyperion** is a high-potency **zinc-based** antimicrobial additive.
- ✓ Having a **core shell- nanopillar morphological structure**.
- ✓ It can kill, reduce and prevent the growth of harmful microorganism (e.g.: *bacteria, virus, fungi, algae*).
- ✓ Having an antimicrobial activity up to **99.9 % (test method: ISO22196)**.
- ✓ Can be **seamlessly incorporated in a wide range of end-use products during the manufacturing process without interfering with the actual manufacturing setup**.




HYPERION Additive
– greyish powder



Key Features



Area of Application



PLASTICS AND POLYMERS (Food-grade and non food-grade)

List of polymers compatible with PATHOGLAZE:

- i. Commodity thermoplastics (*i.e.*: PE, PS)
- ii. Engineering thermoplastics (*i.e.*: PC, ABS, PC/ABS, PA)
- iii. Thermosets (*i.e.*: epoxy)
- iv. Synthetic rubber (*i.e.*: NBR and EPDM)

PAINTS AND COATINGS

PATHOGLAZE

Polymer compound

- ✓ Our **PATHOGLAZE®** additives are compatible with almost all plastics and polymer materials (*i.e.: trial for PP, PC and ABS*).
- ✓ With **0.5%** of PATHOGLAZE loading = **99.9%** of antimicrobial activity (ISO22196)
- ✓ Seamlessly compound in polymer using the existing process
- ✓ Embedded within the polymer compound itself, delivering continuous protection against microbes without affecting gloss or matte surfaces, color, durability, and properties.

In-polymer Food Contact Test according to


- **US FDA 21 CFR 177.1520**

PASS

Migration Test according to Commission Regulation (EU)

- **EU 10/2011 Article 3 of European Regulation 1935/2004***

PASS



PP compound with **0.5%** of **PATHOGLAZE**





Potential
PATHOGLAZE
APPLICATION



Housewares:

Cutting boards, wall coverings, appliances,
toilet seats, flooring, mattresses



Commercials:

PVC blinds, car interiors, packaging, signs,
electronics, seating



Fitness:

yoga mats, footwear, duffle bags,
sports equipment



Construction materials:

flooring, vinyl siding, windows, insulation,
piping, roofing membranes



Healthcare:

business supplies, medical devices, seating,
countertops, storage

PATHOGLAZE

Antimicrobial Packaging (primary & secondary)


- i. Prevents the growth of bacteria and fungi on the surface.
- ii. Reduces bacteria in the surrounding area, and reduces the spread of infection.
- iii. Prolongs food shelf life.
- iv. Promotes product reusability and recyclability.



PATHOGLAZE

Thin Film

- ✓ **Thin film** is a **layer of material** with a thickness ranging from a nanometer to micrometer on the surface of a substrate.
- ✓ Harnessing the potential of zinc, PATHOGLAZE thin film is a **zinc-based thin-film** coating.
- ✓ **PATHOGLAZE® thin film** series is particularly targeted for coating on non-porous surfaces *i.e.*; **glass windows, solar panels, touch-sensitive displays, etc.** where transparency coating is a key consideration.



Manufacturing Facility

- ✓ Located in Malaysia
- ✓ Received **Green Project Certification** for PATHOGLAZE Project from GPM Global USA.
- ✓ Received **Malaysia GPM Sustainability Award 2023: Project of the Year**



Questions



Resolution 1

BDO is automatically reappointed at the annual meeting as the auditor of the Company under section 207T of the Companies Act. This resolution authorises the Board to fix the fees and expenses of the auditor.

Ordinary Resolution: That the Board is authorised to fix BDO Auckland’s fees and expenses as the auditor of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,692,355	4,000	500	78.99%	0
Holdings	9	4	1		
Percentage	100.00%	0.00%	0.00%		

Thank you

